Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
Details for the presentations are as follows:
Oral presentation 1
Title: Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)Speaker: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research InstituteDate/Time: Friday, May 9, 2025, from 12:15 PM – 12:30 PM CETPresentation ID: GS-012Oral Session: General Session 2
Oral presentation 2
Title: Alignment of response assessed by non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in metabolic dysfunction associated steatohepatitis (MASH) clinical trials: a new roadmap for robust drug efficacy assessment demonstrated in the HARMONY trialSpeaker: Prof. Quentin M. Anstee, Ph.D., FRCP, Ruth & Lionel Jacobson Chair of Personalised Medicine, Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UKDate/Time: Saturday, May 10, 2025, from 10:30 – 10:45 CETPresentation ID: OS-096Oral Session: MASLD: Clinical and therapeutical aspects II
Poster presentation
Title: qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY studyPresenter: Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of SaarlandDate/Time: Saturday, May 10, 2025, from 8:30 – 16:00 CETPresentation ID: TOP-458Session: Poster - MASLD: Therapy
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:Christina TartagliaPrecision AQ212.362.1200christina.tartaglia@precisionaq.com
Media Contact:Peg RusconiDeerfield Group617.910.6217Peg.rusconi@deerfieldgroup.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
QuidelOrtho (QDEL) Q2 Earnings Report Preview: What To Look For
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) will be reporting results this Tuesday afternoon. Here's what you need to know. QuidelOrtho met analysts' revenue expectations last quarter, reporting revenues of $692.8 million, down 2.6% year on year. It was a mixed quarter for the company, with a solid beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting QuidelOrtho's revenue to decline 4.1% year on year to $611 million, in line with the 4.2% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.01 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 4.2% on average. Looking at QuidelOrtho's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 3.5%, beating analysts' expectations by 1%, and Hologic reported revenues up 1.2%, topping estimates by 1.7%. GE HealthCare traded down 8.3% following the results while Hologic was up 2.9%. Read our full analysis of GE HealthCare's results here and Hologic's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. QuidelOrtho is down 21.9% during the same time and is heading into earnings with an average analyst price target of $47.14 (compared to the current share price of $22.81). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
4 hours ago
- Yahoo
Surgery Partners (SGRY) Reports Earnings Tomorrow: What To Expect
Healthcare company Surgery Partners (NASDAQ:SGRY) will be reporting results this Tuesday before market open. Here's what to expect. Surgery Partners met analysts' revenue expectations last quarter, reporting revenues of $776 million, up 8.2% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Is Surgery Partners a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Surgery Partners's revenue to grow 7.1% year on year to $816.1 million, slowing from the 14.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.14 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Surgery Partners has missed Wall Street's revenue estimates four times over the last two years. Looking at Surgery Partners's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Surgery Partners is down 3.4% during the same time and is heading into earnings with an average analyst price target of $31.08 (compared to the current share price of $21.28). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Business Upturn
12 hours ago
- Business Upturn
Presentation Explores the Engineering Behind Starlink's Global Internet Network
Baltimore, MD, Aug. 03, 2025 (GLOBE NEWSWIRE) — Presentation featuring entrepreneur James Altucher dives into the advanced engineering driving Elon Musk's Starlink project and how its satellite network could mark a fundamental shift in communications technology. 'Starlink is the radical new future of the internet,' Altucher says in the presentation. 'It beams fast, reliable, unlimited internet through the air… directly to your device.' Building a 'Mesh' in Space The presentation details how thousands of interconnected satellites in low-Earth orbit create a dynamic, self-adjusting mesh network. 'Elon's satellites are designed to wrap the Earth, forming a network to deliver lightning-fast internet to every inch of the planet,' Altucher explains. This configuration allows data to bypass ground-based congestion and maintain low latency even across vast distances. Next-Generation User Equipment At the device level, the presentation spotlights Starlink's terminal design, which uses electronically steered phased-array antennas. 'This antenna is likely built using parts from one small, off-the-radar company,' Altucher notes This technology allows seamless satellite handoffs and enables stable connectivity on moving platforms such as ships and aircraft. Resilient by Design The presentation underscores Starlink's ability to maintain service in extreme conditions. 'It's being used in the Ukraine conflict, where all other access to internet service has been cut off,' Altucher states, highlighting the network's value as a backup communications grid when traditional infrastructure fails. Scaling Without Ground Constraints By avoiding traditional cabling and tower construction, the presentation suggests Starlink's architecture could make high-speed connectivity accessible at unprecedented scale and cost efficiency. 'There'd be no need to dig up neighborhoods, install cables or build cell towers — all of which cost hundreds of billions of dollars,' Altucher explains. He points to this as the foundation for connecting the remaining billions worldwide who are currently offline. About James Altucher James Altucher is a technology entrepreneur, venture capitalist, and Wall Street Journal bestselling author known for identifying transformative innovations years ahead of the mainstream. Recognized as 'one of the best venture capitalists, angel investors, and tech entrepreneurs in the world', he has been an early supporter of disruptive technologies in streaming, social media, and cryptocurrency. He leads Altucher's Investment Network and hosts The James Altucher Show , which has been downloaded more than 40 million times. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
